Dublin, March 07, 2017 -- Research and Markets has announced the addition of the "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition" report to their offering.
The Worldwide Market for In Vitro Diagnostic Tests, represents the 10th edition of this comprehensive look at the IVD industry. At 1,600 pages report provides market size estimates and projections for the entirety of the clinical diagnostics testing market. It also profiles hundreds of competitors, notes significant acquisitions and other deals, discusses trends and breaks out regional and country markets.
The report provides market size and forecasts to 2021 for defined segments of the IVD market and various sub-segments, including:
- Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
- Clinical Chemistry (General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
- Point-of-Care (POC), (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
- Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
- Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
- Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC, HPV)
- Microbiology Immunoassay Testing (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
- Hematology
- Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
- Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
- Coagulation Tests (Lab-Based, POC, Genetic Markers)
No other report provides similar understanding of the world diagnostics market. For each of the listed segments, 2016 market size, 2021 projection and compound annual growth rate is provided, as well as significant companies in the market and product innovations. The market data is put into a context with real-world industry and medical practice trends.
For more information about this report visit http://www.researchandmarkets.com/research/mf27ss/the_worldwide
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Oncology Drugs , In Vitro Diagnostics, Point-of-Care Diagnostics


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



